Gluthatione-S-transferase P1 polymorphism I105V in familial and sporadic prostate cancer

被引:20
作者
Debes, JD
Yokomizo, A
McDonnell, SK
Hebbring, SJ
Christensen, GB
Cunningham, JM
Jacobsen, SJ
Tindall, DJ
Liu, WG
Schaid, DJ
Thibodeau, SN
机构
[1] Mayo Clin, Coll Med, Mayo Clin & Mayo Fdn, Dept Urol, Rochester, MN 55905 USA
[2] Mayo Clin, Coll Med, Mayo Clin & Mayo Fdn, Dept Biochem Mol Biol, Rochester, MN 55905 USA
[3] Mayo Clin & Mayo Fdn, Lab Med & Pathol, Rochester, MN 55905 USA
[4] Mayo Clin & Mayo Fdn, Genet Lab, Rochester, MN 55905 USA
关键词
D O I
10.1016/j.cancergencyto.2004.03.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Several reports suggest that the glutathione-S-transferase (GST) family of enzymes is involved in a variety of cancers, due to their carcinogen-detoxification properties. A polymorphism in codon 105 of the pi variant (GSTP1 I105V), which affects the enzymatic activity of the enzyme, has been linked to the incidence of cancers from different organs. However, the published data in prostate cancer (PCa) is controversial. Some studies report an association with the GSTP1 I105V polymorphism and sporadic PCa, whereas other studies report no association. Recently, one study showed a positive correlation between the GSTP1 I105V polymorphism and familial PCa in a Japanese population. In the present study, we assessed the correlation of the GSTP1 I105V polymorphism with familial and sporadic PCa in an American population. We analyzed DNA samples from 438 patients with familial PCa, 499 patients with sporadic PCa, and 5 10 controls. We found no significant association between the GSTP1 I105V polymorphism and familial or sporadic PCa when compared to the control group [odds ratio (OR) 1.0 (0.74-1.37); P = 0.58]. Moreover, no association was found after stratification for age of diagnosis, Gleason grade, or lymph node involvement [OR = 0.84 (0.65-1.09), P = 0.37]. These data indicate that there is no associated risk for sporadic or familial PCa in American families containing the GSTP1 I105V polymorphism. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:82 / 86
页数:5
相关论文
共 19 条
[1]   Evidence for a prostate cancer-susceptibillty locus on chromosome 20 [J].
Berry, R ;
Schroeder, JJ ;
French, AJ ;
McDonnell, SK ;
Peterson, BJ ;
Cunningham, JM ;
Thibodeau, SN ;
Schaid, DJ .
AMERICAN JOURNAL OF HUMAN GENETICS, 2000, 67 (01) :82-91
[2]   Identification of genetic polymorphisms at the glutathione S-transferase Pi locus and association with susceptibility to bladder, testicular and prostate cancer [J].
Harries, LW ;
Stubbins, MJ ;
Forman, D ;
Howard, GCW ;
Wolf, CR .
CARCINOGENESIS, 1997, 18 (04) :641-644
[3]   Structure-activity relationships and thermal stability of human glutathione transferase P1-1 governed by the H-site residue 105 [J].
Johansson, AS ;
Stenberg, G ;
Widersten, M ;
Mannervik, B .
JOURNAL OF MOLECULAR BIOLOGY, 1998, 278 (03) :687-698
[4]  
Kokoris M, 2000, MOL DIAGN, V5, P329
[5]   Relationship between glutathione S-transferase M1, P1 and T1 polymorphisms and early onset prostate cancer [J].
Kote-Jarai, Z ;
Easton, D ;
Edwards, SM ;
Jefferies, S ;
Durocher, F ;
Jackson, RA ;
Singh, R ;
Ardern-Jones, A ;
Murkin, A ;
Dearnaley, DP ;
Shearer, R ;
Kirby, R ;
Houlston, R ;
Eeles, R .
PHARMACOGENETICS, 2001, 11 (04) :325-330
[6]   Glutathione S-transferase GSTP1 genotypes are associated with response to androgen ablation therapy in advanced prostate cancer [J].
Luscombe, CJ ;
French, ME ;
Liu, S ;
Saxby, MF ;
Farrell, WE ;
Jones, PW ;
Fryer, AA ;
Strange, RC .
CANCER DETECTION AND PREVENTION, 2002, 26 (05) :376-380
[7]  
Mitrunen K, 2001, CANCER EPIDEM BIOMAR, V10, P229
[8]  
Nakazato H, 2003, ANTICANCER RES, V23, P2897
[9]   SERUM PROSTATE-SPECIFIC ANTIGEN IN A COMMUNITY-BASED POPULATION OF HEALTHY-MEN - ESTABLISHMENT OF AGE-SPECIFIC REFERENCE RANGES [J].
OESTERLING, JE ;
JACOBSEN, SJ ;
CHUTE, CG ;
GUESS, HA ;
GIRMAN, CJ ;
PANSER, LA ;
LIEBER, MM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (07) :860-864
[10]  
Park JY, 1999, PHARMACOGENETICS, V9, P497